Deciphera Pharmaceuticals LLC
1505 Wakarusa Drive
Lawrence
Kansas
66047
Tel: 785-838-3767
Fax: 785-838-3747
Website: http://www.deciphera.com/
Email: deciphera@deciphera.com
148 articles with Deciphera Pharmaceuticals LLC
-
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones
1/11/2021
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference.
-
Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET.
-
Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
11/30/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST).
-
Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/24/2020
Deciphera Pharmaceuticals, Inc announced that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
-
The Boston Globe Names Deciphera a Top Place to Work for 2020
11/23/2020
Deciphera Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the Top Places to Work in Massachusetts in the 13th annual employee-based survey project from The Boston Globe.
-
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
11/11/2020
– Preliminary Results Showed 41% (9 of 22 Patients) Objective Response Rate, Including One Confirmed Complete Response – – Treatment was Generally Well-Tolerated with Treatment-Emergent Adverse Events Mostly Grade 1 or 2 – – Based on Preliminary Results, the Expansion Cohorts for DCC-3014 in TGCT Patients Opened at the Recommended Phase 2 Dose of 30 mg Twice Weekly –
-
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
11/11/2020
– Deciphera Presents the First and Largest Baseline Genomic Analysis by Tumor and Liquid Biopsy in Fourth-line Patients with GIST – – Results from an Exploratory Analysis of the Phase 3 INVICTUS Study in Fourth-line GIST Demonstrate the Broad Clinical Activity of QINLOCK Across Mutation Sub-groups –
-
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
11/10/2020
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
-
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
11/5/2020
Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway
-
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020
10/28/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Thursday, November 5, 2020, to discuss the Company’s financial results and provide a corporate update. The conference call may be
-
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
9/18/2020
Deciphera Pharmaceuticals, Inc., announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST.
-
Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
9/17/2020
- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer - - Rebastinib Combined with Carboplatin was Well-tolerated in Patients with Metastatic Solid Tumors and Showed Initial Clinical Activity - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of data from the ovarian
-
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
8/17/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST).
-
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
-
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
8/6/2020
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40 th Annual Growth Conference
-
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
8/4/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments.
-
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
7/29/2020
Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.
-
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
7/14/2020
QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status
-
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
7/2/2020
Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who crossed over t
-
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
6/22/2020
QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study